1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

17 Oct 2022
Admin
News Article

Novavax Announces Positive Results From Phase 1/2 Trial Of Its Covid-19-Influenza Combination Vaccine Candidate

Novavax, Inc., A Biotechnology Company Dedicated To Developing And Commercializing Next-Generation Vaccines For Serious Infectious Diseases, Announced Positive Results From The Phase 1/2 Clinical Trial Of Its Covid-19-Influenza Combination (Cic) Vaccine Candidate. Data Demonstrated The Cic Vaccine'S Ability To Generate Immune Responses, Including Both Antibody And Polyfunctional Cd4+ T-Cell (Lymphocytes That Help Coordinate The Immune Response) Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) And Homologous And Heterologous Influenza Strains. The Cic Combines Novavax' Covid-19 Vaccine (Nvx-Cov2373) And Its Quadrivalent Influenza Vaccine Candidate.The Cic Vaccine Formulations Demonstrated Induction Of Polyfunctional Cd4+ T-Cell Responses Against Both Sars-Cov-2 And Homologous And Heterologous Influenza Strains At Levels Comparable To Stand-Alone Nvx-Cov2373 And Quadrivalent Influenza Vaccine Candidate Reference Formulations. Nvx-Cov2373 Has Previously Been Shown To Induce Functional Sars-Cov-2

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!